Community-acquired lobar pneumonia in children in the era of universal 7-valent pneumococcal vaccination: a review of clinical presentations and antimicrobial treatment from a Canadian pediatric hospital by Anne Rowan-Legg et al.
Rowan-Legg et al. BMC Pediatrics 2012, 12:133
http://www.biomedcentral.com/1471-2431/12/133RESEARCH ARTICLE Open AccessCommunity-acquired lobar pneumonia in
children in the era of universal 7-valent
pneumococcal vaccination: a review of clinical
presentations and antimicrobial treatment from a
Canadian pediatric hospital
Anne Rowan-Legg1*†, Nicholas Barrowman2, Nazih Shenouda3, Khaldoun Koujok3 and Nicole Le Saux1†Abstract
Background: Community-acquired pneumonia (CAP) is a common cause of pediatric admission to hospital. The
objectives of this study were twofold: 1) to describe the clinical characteristics of CAP in children admitted to a
tertiary care pediatric hospital in the pneumococcal vaccination era and, 2) to examine the antimicrobial selection
in hospital and on discharge.
Methods: A retrospective review of healthy immunocompetent children admitted to a tertiary pediatric hospital
from January 2007 to December 2008 with clinical features consistent with pneumonia and a radiographically-
confirmed consolidation was performed. Clinical, microbiological and antimicrobial data were collected.
Results: One hundred and thirty-five hospitalized children with pneumonia were evaluated. Mean age at admission
was 4.8 years (range 0–17 years). Two thirds of patients had been seen by a physician in the 24 hours prior to
presentation; 56 (41.5%) were on antimicrobials at admission. 52 (38.5%) of patients developed an effusion, and
22/52 (42.3%) had pleural fluid sampled. Of 117 children who had specimens (blood/pleural fluid) cultured, 9 (7.7%)
had pathogens identified (7 Streptococcus pneumoniae, 1 Group A Streptococcus, and 1 Rhodococcus). 55% of
patients received 2 or more antimicrobials in hospital. Cephalosporins were given to 130 patients (96.1%) in
hospital. Only 21/126 patients (16.7%) were discharged on amoxicillin. The median length of stay was 3 days
(IQR 2–4) for those without effusion and 9 (IQR 5–13) for those with effusion. No deaths were related to pneumonia.
Conclusions: This study provides comprehensive data on the clinical characteristics of hospitalized children with
CAP in the pneumococcal 7-valent vaccine era. Empiric antimicrobial choice at our institution is variable, highlighting
a need for heightened antimicrobial stewardship.Background
Pediatric community-acquired pneumonia (CAP) is a com-
mon and potentially serious childhood infection, which
often results in hospital admission. The World Health
Organization has estimated that in developed countries,
one in twenty children under the age of five years will have
an episode of pneumonia each year, and 1 to 4 per 1000* Correspondence: arowanlegg@cheo.on.ca
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distribution, and reproduction in any mediumchildren are admitted to hospital annually [1]. S. pneumo-
niae continues to be the most important pathogen in bac-
terial pneumonia. The 7-valent pneumococcal conjugate
vaccine (PrevnarW, PCV-7) became available in Canada in
2000, and was added to the routine Ontario immunization
schedule in January 2005 [2]. Introduction of the pneumo-
coccal vaccine has been shown to decrease all-cause radio-
logic pneumonia admission rates by an average of 27% in
children under the age of 5 years [3-10].
The diagnostic and therapeutic approach to pneumonia
in children is not standardized. The diagnosis of CAP inntral Ltd. This is an Open Access article distributed under the terms of the
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showing consolidation (alveolar infiltrates) or consolida-
tion complicated by effusion. It has been suggested that a
radiographic pattern of alveolar infiltrates is most fre-
quently associated with bacterial infection [11]. Available
clinical guidelines for empiric treatment of pediatric CAP
are largely based on consensus opinion [12-14] This likely
relates to low rates of pathogen identification, the
spectrum of severity, and a paucity of randomized con-
trolled trials to guide antimicrobial therapy. Without
evidence-based guidelines, antimicrobial treatment of
pediatric CAP has been shown to be variable in both in-
patient and outpatient settings, with a tendency to overuse
broad spectrum antimicrobials [15-18].
We conducted a retrospective study of healthy chil-
dren admitted to hospital with CAP (based on presenta-
tion of consolidative pneumonia and compatible clinical
symptoms) to describe their clinical course and manage-
ment, in the era of PCV-7 vaccination.Methods
Study location
The Children’s Hospital of Eastern Ontario (CHEO, Ottawa,
Canada) is an urban, tertiary pediatric care centre with a
catchment population of over 2,000,000 people (eastern
Ontario, western Quebec and Baffin Island) [19]. It is the
only hospital in the catchment area that admits children.
The Children’s Hospital of Eastern Ontario does not have
empiric management guidelines for CAP.Study design
A retrospective chart review of admitted children with
ICD-10 discharge codes of ‘pneumonia’, ‘empyema’, ‘para-
pneumonic effusion’, ‘pyothorax’, or ‘pleural effusion’ from
January 1, 2007 to December 31, 2008 was conducted. We
excluded any child that had an associated underlying con-
dition coded at the time of the pneumonia.
The admitting chest radiograph (CXR) reports (as
reported by pediatric radiologists) were classified by 2
independent reviewers (AR-L and NLS) as reporting:
i) definite consolidation, ii) no consolidation, or iii) ‘pos-
sible’ consolidation. Only cases that had definite consoli-
dation, or consolidation associated with an effusion,
were included for further review.
Two pediatric radiologists independently reviewed a
sample of 31 of the CXRs (without access to the CXR re-
port) and were asked to indicate whether the CXR had a
definite consolidation. (Of these 31 cases, 6 had been
previously excluded by AR-L/NS on the basis of an
equivocal or negative CXR report for consolidation, and
25 were a random sample of those included in the final
study analysis.) Kappa values were calculated to ensure
agreement between reviewers.Each chart was subsequently reviewed to determine if
the patient met the study inclusion criteria: i) age 0–
18 years, and ii) no underlying chronic illnesses that
would predispose to aspiration or pneumonia. Exclusion
criteria were as follows: i) presence of a comorbid condi-
tion [e.g. hemodynamically significant heart disease, ma-
lignancy, hemoglobinopathy, underlying pulmonary
pathology (e.g. cystic fibrosis, bronchiectasis or broncho-
pulmonary dysplasia), cerebral palsy or other chronic
neurological disease, upper airway mechanical problems
(e.g. tracheostomy, stenosis), or genetic syndrome], or ii) a
clinical history incompatible with pneumonia. Neither
asthma nor prematurity were considered exclusion criteria.
A standardized case report form was developed to col-
lect demographic, clinical, diagnostic, treatment and out-
come data on all cases meeting inclusion criteria. The
medical record was systematically reviewed by one of
four independent reviewers (AR-L, NL, CG, MB). Hypoxia
was defined as an oxygen saturation ≤ 92%. Tachypnea
was defined according to the World Health Organization
definition: <2 months: respiratory rate (RR) ≥60 breaths/
minute, 2 – 12 months: RR ≥50 breaths/minute, 1–5 years:
RR ≥40 breaths/minute and >5 years: RR >30 breaths/
minute [20]. A large effusion was defined as involving ≥ 2/3
of the hemithorax.
The total length of antimicrobial therapy included the
number of days of antimicrobials administered in hospital
in addition to those prescribed at discharge. The principal
antimicrobial used in hospital was defined as the anti-
microbial(s) given for the longest time period in hospital.
Discrete variables were summarized using frequency
and percentage. Continuous variables were summarized
using mean and standard deviation or median and inter-
quartile range, as appropriate. Proportions were com-
pared using Pearson’s chi-square test or Fisher’s exact
test, as appropriate. Association between patient age and
presence of an effusion was assessed using binary logistic
regression. Kappa values were calculated between the
two radiologists, and between AR-L/NS and each of the
two radiologists separately. All analyses were performed
using SPSS version 19.0.2 [21].
The study was approved by the Research Ethics Board
at the Children’s Hospital of Eastern Ontario (2009).
Results
Study population
Two-hundred and thirty-two patients had eligible ICD-
10 discharge codes for entry into the study. Of those,
143 patients met the criteria of having a definite consoli-
dation on CXR report. In a sample of 31/143 charts,
moderate agreement (k = 0.52) was found between the
judgments of two independent radiologists (NS and KK)
for the presence of consolidation. The agreement be-
tween AR-L/NS and one radiologist was substantial
Table 2 Clinical course in hospital of patients admitted
with pneumonia (n =135)
Fever (≥38.0°C) at triage; n (%) 51 (37.8)
Hypoxia (O2 saturation ≤92%)
at triage; n (%)
31 (23.0)
Tachypnea (WHO classification)
at triage; n (%)
61 (45.2)
Initial white blood cell count (x 109/L);
mean (SD) [range] – median (IQR)
17.23 (9.64) [1.29-54.2] –
14.9 (9.6-23.1)
Days of fever (≥38.0°C);
in hospital; mean (SD)
1.88 (2.58)
Developed a supplemental O2
need in hospital; n (%)
44 (32.6)
Days requiring supplemental O2 in those
children requiring O2 therapy; mean (SD)
3.92 (4.13)
Length of stay (days): median (IQR)
All patients 4 (3–8)
Patients without effusion 3 (2–4)
Patients with effusion 9 (5–13)
Admission to intensive care unit; n (%) 13 (9.6)
Deaths; n (%) 0 (0)
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was moderate (k = 0.44) [22].
After chart review, 135 patients met inclusion criteria.
The reasons for patient exclusion were: 5 had underlying
conditions (e.g. cerebral palsy, alpha-1-antitrypsin defi-
ciency, hepatitis A, and congenital cystic adenomatoid mal-
formation), and 3 had a clinical history incompatible with
pneumonia (i.e. respiratory symptoms on hospital admis-
sion were better accounted for by conditions such as severe
reactive airway disease, croup, or aspiration). See Table 1
for demographic characteristics of the study population.
The most common pre-admission clinical signs were
fever (94.1%), cough (89.6%), decreased oral intake
(71.9%), vomiting (53.3%) and nasal congestion (49.6%).
The clinical features of the course in hospital are out-
lined in Table 2.
Of the 135 patients, 75 (56%) had one CXR, 24 (18%) had
two CXRs, and 34 (25%) had≥3 CXRs. Two patients had
an initial CXR done at an external hospital. One patient
(admitted to the intensive care unit) had 29 CXRs done.
Pneumonia with effusion
Effusions were identified on CXR in 52 (38.5%) patients;
46 (34.1%) were identified on admission and 6 developed
in hospital.Table 1 Demographic characteristics of study population
(n =135)
Age at admission (years); mean (SD) [range] 4.8 (3.9) [0–17 years]
Sex (male); n (%) 76 (56.3)
Prematurity (gestational age <37 weeks); n (%) 9 (6.7)
Month of admission: n (%)
January – March 47 (34.8)
April – June 30 (22.2)
July – September 25 (18.5)
October – December 33 (24.4)
Length of history of symptoms (days); median (IQR)
Patients without effusion 4 (3–7)
Patients with effusion 7 (5–10)
Fever prior to presentation; n (%) 127 (94.1)
Previous visit to physician in prior
24 hours documented; n (%)
86 (63.7)
Antimicrobials prescribed prior to
presentation documented; n (%)
56 (41.5)
Hospitalization for asthma in past year; n (%) 3 (2.2)
Attendance at daycare or school documented;
n (%)
100 (74.1)
Up to date immunizations documented; n (%) 120 (88.9)
Admitted from: n (%)
CHEO Emergency Department 108 (80)
Transferred from peripheral hospital as outpatient 17 (12.6)
Transferred from peripheral hospital as inpatient 10 (7.4)Patients with effusions had a longer duration of pre-
admission symptomatology (7 vs 4 days) but were not
more likely to be febrile (p = 0.58), tachypneic (p = 0.58),
or have a higher white blood cell count (p = 0.90) com-
pared to those without effusion. The presence of an effu-
sion was not associated with age (p = 0.89). Patients with
effusions had a longer length of stay compared to chil-
dren with uncomplicated pneumonia (9 vs 3 days).
Chest ultrasound was performed in 28/52 (53.8%) of
patients with effusion, and 16/52 (30.8%) had computer-
ized tomography of the chest for diagnostic purposes. Of
this group, 23/52 (44.2%) had a chest tube or pigtail
catheter inserted and 14/52 (26.9%) underwent a video-
assisted thoracoscopic (VATS) procedure.
Pleural fluid was sampled in 22/52 (42.3%) of patients
with an effusion a median of 4 days after admission
(IQR 1–6). All samples were obtained after antimicro-
bials had been started.
Of the patients without effusion, 3/83 (3.6%) were ad-
mitted to the ICU, whereas 10/52 (19.2%) of patients
with effusion were admitted to the ICU, showing that
the presence of an effusion is significantly associated
with ICU admission (p = 0.005).Microbiology
Bacteremic pneumonia
7 (6.0%) of 117 patients who had blood cultures taken
had a bacteremic pneumonia; 6 (86%) grew S. pneumo-
niae and 1 grew Rhodococcus species (5 year-old im-
munocompetent girl with acute onset of fever and
consolidative pneumonia). Additionally, 2 blood cultures
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coccus, Staphylococcus epidermidis).
Pleural fluid
Of 22 patients who had pleural fluid sampled, 3 (13.6%)
had a positive gram stain (1 Gram positive cocci and
Gram negative cocci, and 2 Gram positive cocci) while 2
(9.1%) had a positive pleural fluid culture (Group A
Streptococcus and S. pneumoniae). These latter 2 patients
were not bacteremic.
Of the 7 identified S. pneumoniae serotypes in blood or
pleural fluid, three were 19A (one from pleural fluid, two
from blood), two were serotype 3, one was 11A, and one
was 9 V.
Mycoplasma testing
Of 12 (8.9%) patients tested for Mycoplasma by throat
swab PCR 3/12 (25%) were positive. 46 (34.1%) were
tested for Mycoplasma by IgM serology and 13 (28.3%)
were positive.
Viral testing
Throat or nasopharyngeal swab for viral culture or anti-
gen detection was done in 61 patients (45.1%), and 7
(11.5%) were positive: 5 with respiratory syncytial virus,
1 enterovirus, and 1 herpes simplex virus Type 1.
Antimicrobial usage
The most frequently prescribed combinations of antimi-
crobials during hospitalization are summarized in Table 3.
Of the patients that had documented S. pneumoniae (all
penicillin susceptible) in a blood or pleural fluid sample, 2
received penicillins, 2 received vancomycin and a third gen-
eration cephalosporin, 1 received ceftriaxone, 1 received
cefuroxime and clindamycin, and 1 received cefuroxime
alone. At discharge, 2 of these patients received amoxicillin,
3 patients received amoxicillin-clavulinic acid, 1 was dis-
charged without antimicrobials, and 1 continued intraven-
ous ceftriaxone (to treat a lung abscess).Table 3 Frequency of principal antimicrobial use during
hospital admission (n= 135)
Antimicrobial (s) Frequency (n = 135)
Cefuroxime; n (%) 60 (44.4)
Cefuroxime and Clarithromycin; n (%) 36 (26.7)
Cefuroxime and Clindamycin; n (%) 15 (11.1)
Ampicillin; n (%) 2 (1.5)
Penicillin; n (%) 3 (2.2)
Ceftriaxone and Clindamycin; n (%) 4 (2.9)
Clindamycin and Clarithromycin; n (%) 2 (1.5)
Ceftriaxone; n (%) 1 (0.7)
Clarithromycin; n (%) 1 (0.7)
Other; n (%) 11 (8.1)Of the 83 patients with uncomplicated pneumonia, 40
(48.2%) received 1 antimicrobial, 33 (39.8%) received 2,
8 (9.6%) received 3, and 2 (2.4%) received four antimi-
crobials (simultaneously or consecutively) while in hos-
pital. Of the 52 patients with an effusion, 7 (13.5%)
received 1 antimicrobial, 20 (38.5%) received 2, 14
(26.9%) received 3, 7 (13.5%) received four, and 4 (7.7%)
received 5 antimicrobials over the course of their stay.
Only 47 patients (34.8%) received one antimicrobial dur-
ing admission; 46 (97.9%) received cefuroxime and one
received clarithromycin. A third generation cephalosporin
was given to 15 (11.1%) of children. A macrolide was used
in hospital or at discharge in 77/135 (57.0%) of patients.
Patients under 5 years of age received a macrolide in hos-
pital or at discharge in 38/83 (45.8%) of cases, compared
to 39/52 (75.0%) of patients 5 years and older (p= 0.001).
The antimicrobials prescribed at discharge for patients
with and without effusion are included in Table 4.
Length of antimicrobial treatment
The median total length of antimicrobial therapy for all
patients was 12 days (IQR 10 – 16). For those patients
without effusion, the median length of treatment was
10 days (IQR 10 – 12), while those with effusion was
18.5 days (IQR 14 – 25).
Discussion
This study is a review of pediatric CAP (diagnosed by con-
solidation on initial chest radiograph and compatible clin-
ical history) at a pediatric hospital, two years after the
introduction of universal PCV-7 pneumococcal vaccin-
ation. Previous reviews have had smaller sample size, were
less comprehensive, were limited to developing nations, or
were completed prior to the introduction of the conju-
gated seven valent pneumococcal vaccine [10,23-25].
Since the diagnosis of CAP is often based on a com-
patible clinical presentation and a CXR finding of con-
solidation, we chose these as practical requirements for
study inclusion. Our sample selection was an attempt to
increase the probability of capturing and evaluating bac-
terial pneumonias given that consolidation is most fre-
quently associated with bacterial infection [11,26-28].
The small sample size of the radiographs that were
reviewed by the radiologists likely resulted in the low
kappa scores. These values are comparable to published
results, and acknowledge the inter-observer variability in
interpretation of chest radiographs in the absence of
clinical information [11,28].
This study supports the significant continuing health
care burden of children hospitalized with consolidative
pneumonia in the era of PCV-7 use. [29] In this cohort,
two-thirds of patients had at least one visit to a phys-
ician prior to their hospitalization and the average length
of hospital stay was 4 days. One quarter of children had
Table 4 Discharge antimicrobials for patients without effusion (n =83) and with effusion (n = 52)
Without effusion (n = 83) With effusion (n = 52)
No Antimicrobials; n (%) 5 (6.0) 4 (7.7)
Amoxicillin; n (%) 16 (19.3) 5 (9.6)
Amoxicillin-Clavulinic Acid; n (%) 23 (27.7) 20 (38.5)
Cefuroxime OR Cefprozil 14 (16.9) 11 (21.1)
Clarithromycin OR Azithromycin OR Erythromycin; n (%) 17 (20.5) 6 (11.5)
Both Amoxicillin AND (Clarithromycin OR Azithromycin); n (%) 4 (4.8) 3 (5.8)
Other; (%) 4 (4.8) 3 (5.8)
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cedure done (chest tube insertion or VATS).
Our study found that patients presenting with effusion
were not more likely to be younger, febrile, tachypneic
or have a higher WBC count than those without effu-
sion, underscoring the importance of chest radiography
in pediatric CAP. Other authors have supported the im-
portance of early radiologic evaluation in differentiating
early complicated versus uncomplicated lobar pneumo-
nia [25,30]. Children with an effusion were more likely
to be admitted to the intensive care unit.
Only 9 of the 117 (7.7%) patients had bacterial patho-
gens identified in blood or pleural fluid. Seven had
Streptococcus pneumoniae (6 in blood and 1 in pleural
fluid) and 1 child had Group A streptococcus isolated
from pleural fluid. The incidence of bacteremia was 6%,
which is comparable to a recent study evaluating chil-
dren with CAP in the Emergency Department [31], but
lower than bacteremic rates published previously in the
literature [12,32]. This is likely due to the fact that 42%
of children in this cohort had antimicrobials prior to
hospital presentation.
PCV-7 has been included in the publicly-funded routine
immunization schedule in Ontario since 2005. By parental
report, the majority of children had up-to-date vaccination
series for age. Six of the seven S. pneumoniae serotypes
identified in blood or pleural cultures were not PCV-7 sero-
types, but would have been covered by PCV-13 (Pre-
vnar13W), while one of the seven serotypes would have
been covered by PCV-10 (SynflorixW). (4/6 children with
PCV-13 vaccine serotypes would have been age-eligible for
immunization and therefore had infection potentially pre-
ventable with PCV-13.) The only vaccine-preventable sero-
type (9 V) occurred in a 16-year-old youth who would not
have received PCV-7 immunization. The only bacteremic
serotype in this cohort not included in the 7, 10 or 13-
valent vaccines was 11A.
Current pediatric CAP guidelines and reviews recom-
mend consideration of treatment with intravenous ampicil-
lin or penicillin for hospitalized children, given the evidence
for its comparable effectiveness to cefuroxime for more se-
vere pneumonia. [12-14,33-35]. Despite this, less than 5%
of children received a penicillin as initial therapy. Only 19%of children with uncomplicated pneumonia received amoxi-
cillin at discharge, and only 2 of the 7 patients with con-
firmed S. pneumoniae were discharged on amoxicillin. All
S. pneumoniae isolates in this study were penicillin suscep-
tible. (CHEO’s 2010 Antibiogram reports a 97% susceptibil-
ity of S. pneumoniae to penicillin [36].) Cephalosporins
were prescribed in 96% of patients in this cohort rather
than narrower-spectrum, less expensive antimicrobial
agents, such as penicillin or ampicillin. We acknowledge
that prior antimicrobial use may have influenced the physi-
cian’s antimicrobial choice on admission. Antimicrobial
stewardship intiatives and recently published guidelines
aimed at use of ampicillin or penicillin G (as opposed to
broader spectrum coverage with second and third gener-
ation cephalosporins) may alter prescribing trends in the
future.
Guidelines recommend empiric coverage with a macro-
lide in older children because Mycoplasma pneumoniae is
more prevalent in this group [12-14]. More recent data
has shown that Mycoplasma pneumoniae may play a more
important role in the younger age group than previously
believed [26]. Further studies may alter the current recom-
mendations regarding the use of macrolides in pediatric
CAP, however macrolide use should be cautioned in areas
where there is significant pneumococcal resistance to
macrolides. In this study, macrolides were used frequently
in the younger age group - nearly half of children under
age 5 years were treated with a macrolide either in hospital
or at discharge.
The limitations of the retrospective nature and design
of the study did not permit verification of specific
immunization status for PCV-7. Microbiological data was
also not available for all patients. Our inclusion criteria of
consolidative pneumonia would have excluded patients
with very early pneumonias that did not have established
consolidation on initial CXR. The study results however,
are generalizable to healthy children who are hospitalized
for consolidative pneumonia in populations where PCV-7
is routinely administered to children.
Conclusions
This study shows the substantial and continued morbid-
ity associated with pneumonia in the era of universal
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highly variable at this institution, emphasizing the need
for clear evidence-based guidelines for the management
of pediatric CAP.
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